Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Glycopyrrolate" patented technology

A muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics.

Formulation for soft anticholinergic analogs

PendingAU2024227714B2DiseaseAnticholinergic Drugs
Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis. 20 24 22 77 14 29 O ct 2 02 4 A B S T R A C T 2 0 2 4 2 2 7 7 1 4 2 9 O c t 2 0 2 4
Owner:BODOR LABORATORIES INC

Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) glycopyrrolate; and (iii) a diluent, which diluent comprises water, wherein: the glycopyrrolate is dissolved in the diluent; the concentration of glycopyrrolate is less than or equal to 5.0 mg / mL; and the pH of the liquid pharmaceutical composition is from 3.0 to 6.0. The invention also relates to a nebuliser comprising the liquid pharmaceutical composition.
Owner:VERONA PHARMA

Pharmaceutical composition

PendingUS20260174734A1Dispersion deliverySolution deliveryDifluoroethynePropanoic acid
A pharmaceutical composition comprises a drug component. The drug component is a combination of one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone dipropionate, and one long acting beta-2-agonist (LABA) selected from formoterol and pharmaceutically acceptable salts thereof. The pharmaceutical composition also comprises a propellant component. The propellant component is at least 90 weight percent 1,1-difluoroethane (HFA-152a). The pharmaceutical composition is in the form of a solution and optionally comprises ethanol, but is free of other polar solvents / co-solvents. The drug component is the sole drug component in the pharmaceutical composition.
Owner:MEXICHEM FLUOR S A DE CV